Results for tag: "Lorbrena"

The Lorbrena market is a subset of the larger lung cancer drug market. It is composed of drugs that target a specific genetic mutation known as ALK, which is found in some non-small cell lung cancer (NSCLC) patients. These drugs are designed to target the ALK mutation and inhibit its growth, thus slowing or stopping the progression of the cancer. Lorbrena drugs are typically administered orally, and are often used in combination with other treatments such as chemotherapy and radiation. The Lorbrena market is highly competitive, with several major pharmaceutical companies vying for market share. Companies such as Pfizer, Novartis, and AstraZeneca are all major players in the Lorbrena market, offering a variety of treatments for NSCLC patients with the ALK mutation. Other companies such as Merck, Bristol-Myers Squibb, and Roche also have a presence in the Lorbrena market, offering their own treatments for NSCLC patients. Show Less Read more